After multiple failed attempts by big pharmaceutical and biotech companies to develop a Non-alcoholic Steatohepatitis (NASH) treatment, Madrigal Therapeutics could become the first firm to have its drug, resmetirom, approved for the condition. The company’s Phase 3 trial has returned positive data, with the drug resolving liver biopsy findings in NASH more frequently than the placebo. The NASH treatment market is expected to reach $48.3bn by 2035.
Mustang Panda Uses SnakeDisk USB Worm and Toneshell Backdoor to Target Air-Gap Systems – gbhackers.com
Mustang Panda Uses SnakeDisk USB Worm and Toneshell Backdoor to Target Air-Gap Systems gbhackers.com
